title: Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
abstract: INTRODUCTION The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour. AIM We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC. MATERIAL AND METHOD Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis. RESULTS A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression- free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05). CONCLUSION This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.
authors.affiliation: Department of Oncology, Uludag University Medical School, Bursa, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Cubukcu
authors.forename: O
authors.initials: O
authors.lastname: Fatih Olmez
authors.forename: O
authors.initials: O
authors.lastname: Saraydaroglu
authors.forename: U
authors.initials: U
authors.lastname: Akcali
authors.forename: O
authors.initials: O
authors.lastname: Kanat
authors.forename: E
authors.initials: E
authors.lastname: Kurt
authors.forename: T
authors.initials: T
authors.lastname: Evrensel
authors.forename: O
authors.initials: O
authors.lastname: Manavoglu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin
references.citation: Anticancer Res. 2010 Sep;30(9):3223-32
references.pmid: 20944091
references.citation: Int J Biochem Cell Biol. 2007;39(7-8):1318-28
references.pmid: 17600754
references.citation: Cancer Invest. 2010 Dec;28(10):1078-83
references.pmid: 20504223
references.citation: Biomark Insights. 2010 Feb 09;5:9-20
references.pmid: 20212918
references.citation: Adv Exp Med Biol. 2005;570:45-83
references.pmid: 18727498
references.citation: Cancer Treat Rev. 2007 Oct;33(6):565-77
references.pmid: 17707593
references.citation: Future Oncol. 2010 May;6(5):741-67
references.pmid: 20465389
references.citation: Mutat Res. 2000 Nov 9;461(3):197-210
references.pmid: 11056291
references.citation: Lung Cancer. 2008 Mar;59(3):377-84
references.pmid: 17905465
references.citation: Int J Mol Med. 2004 Dec;14(6):959-70
references.pmid: 15547660
references.citation: N Engl J Med. 2006 Sep 7;355(10):983-91
references.pmid: 16957145
references.citation: Cancer. 2008 Sep 15;113(6):1379-86
references.pmid: 18623378
references.citation: Curr Opin Pulm Med. 2007 Jul;13(4):284-9
references.pmid: 17534174
references.citation: Lung Cancer. 2009 May;64(2):131-9
references.pmid: 18804893
references.citation: J Natl Compr Canc Netw. 2010 Jul;8(7):740-801
references.pmid: 20679538
references.citation: Nat Rev Clin Oncol. 2010 Jul;7(7):401-14
references.pmid: 20551945
references.citation: Clin Lung Cancer. 2010 May;11(3):149-59
references.pmid: 20439190